



DEVELOPING <sup>NEW</sup>  
TUBERCULOSIS VACCINES  
FOR THE WORLD



# EDCTP and Global Partnerships – Aeras Global TB Vaccine Foundation

Dr. Tony Hawkrige  
Aeras Global TB Vaccine Foundation, Africa Office

Fifth EDCTP Forum: Plenary Session VI  
14 October 2009  
Arusha, Tanzania

# Aeras Global TB Vaccine Foundation

## Mission


To develop new, more effective TB vaccines and ensure their availability to all who need them

## Goals


- A more effective, safe and affordable TB vaccine by 2016
- Identify correlates and surrogate markers of vaccine induced protection
- Develop second generation TB vaccines with increased potency and broader protection



# Current TB Vaccine Pipeline



# Partnerships in TB vaccine trials



# Aeras Global Vaccine Development Partners

## Foundations/ Governments/ NGOs


Bill & Melinda Gates Foundation, U.S.  
 Ministry of Foreign Affairs of Denmark  
 The Netherlands Ministry of Foreign Affairs, the Netherlands  
 Fogarty International Center and NIAID, National Institutes of Health, U.S.  
 Research Council of Norway, Norway  
 Maryland Department of Business and Economic Development, United States  
 AIDS Fondet, Denmark  
 Cambodian Health Committee, Cambodia

**European and Developing Countries Clinical Trials Partnership (EDCTP), European Commission**

LHL/ The Norwegian Association of Heart and Lung Patients, Norway  
 Planeta Salud, Spain

**Manhiça Health Research Centre, Mozambique**

Medicine in Need (MEND), U.S.  
 Stop TB Partnership, Switzerland  
 TB-Alert, United Kingdom  
 Wellcome Trust, United Kingdom



## Industry

GlaxoSmithKline Biologicals, Belgium  
 Crucell, the Netherlands  
 Statens Serum Institute, Denmark  
 ImmunoBiology, United Kingdom  
 Wuhan Institute of Biological Products, China  
 Serum Institute, India  
 Thymed, Germany  
 Japan BCG Laboratory, Japan  
 Korean Institute of TB, Korea  
 Cyncron, Denmark  
 Immune Solutions, New Zealand  
 Sanofi Pasteur, France  
 Smittskyddsinstytutet, Sweden  
 Emergent BioSolutions, U.S.  
 Intercell, Austria  
 Bioland, Korea

## Academia


Oxford University, United Kingdom  
**South African TB Vaccine Initiative (SATVI), South Africa**  
 St. Johns Research Institute, India  
**Makerere University, Uganda**  
**Kenya Medical Research Institute, Kenya**  
 Karolinska Institute, Sweden  
 Wuhan University, China  
 Albert Einstein College of Medicine, U.S.  
 Arizona State University, U.S.

**Aurum Institute, South Africa**

Biomedical Primate Research Center, the Netherlands  
 Case Western Reserve University, U.S.  
 Centre for International Health, University of Bergen, Norway  
 Colorado State University, U.S.  
 Emory University, U.S.  
 Food and Drug Administration, U.S.  
 Foundation for Innovative New Diagnostics (FIND), Switzerland  
 Harvard University, U.S.  
 International AIDS Vaccine Initiative (IAVI), U.S.  
 Johns Hopkins University, U.S.  
 KNCV Tuberculosis Foundation, the Netherlands  
 Leiden University Medical Center, the Netherlands  
 Life Science Research Israel (LSRI), Israel  
 Max Planck Institute for Infection Biology, Germany  
 National Cancer Institute (NKI), the Netherlands  
 Oregon Health Sciences University, U.S.  
 Stanford University, U.S.  
 Saint Louis University., U.S.  
 Tuberculosis Vaccine Initiative (TBVI), Europe  
 University of California-San Francisco, U.S.  
 University of California-Los Angeles, U.S.  
 University of Maryland, College Park, U.S.  
 University of Tampere, Finland  
 University of Wales, United Kingdom  
 Vanderbilt University., U.S.  
 Walter Reed Army Institute of Research, U.S.


# Aeras Partnerships with Clinical Trial Sites

## Many are also EDCTP funded sites/groups




# Examples of EDCTP – Aeras partnerships

- 2005/6 EDCTP call for capacity building at potential TB vaccine trial sites.
- Successful proposals from KEMRI-CDC, Kisumu (PI Nduba) and IDI/Makarere University, Kampala (PI Musoke).
- Large cohort studies in infants and adolescents underway at both sites.
- Aeras co-supporting these activities in cash and in kind.




# Examples of EDCTP – Aeras partnerships

- EDCTP 2007 call  
IP\_07\_32080 Capacity development for the  
conduction of phase 2b and 3 efficacy  
trials of new TB vaccines in Africa
- Consortium consisting of 4  
African partners [SAF, KEN,  
UGA, MOZ], and 6 European  
partners [NET, SWE, BEL, SWI,  
AUS, SPA] submitted proposal  
built around Phase IIB trial of  
AERAS 402 in 1600 infants at 4  
African sites.
- Aeras is sponsor and co funder  
(with EDCTP) of trial.



# Examples of EDCTP – Aeras partnerships



- **EDCTP 2007**  
IP\_07\_32080 Capacity development for the  
conduction of phase 2b and 3 efficacy  
trials of new TB vaccines in Africa
- Consortium consisting of  
PI's Wilkinson (SA), Ota  
(The Gambia) and Mboup  
(Senegal) submitted  
successful proposal for trial  
of MVA85A/AERAS485 in  
HIV+ adults at 3 sites
- Aeras agreed to be legal  
sponsor of trial.

## **Possible example of another EDCTP – Aeras partnership**

- EDCTP 2009 call (due 15<sup>th</sup> December 2009)
- **Call for the support of clinical trials, capacity building and networking in tuberculosis vaccines development**
- Integrated Project (Clinical Trials/Capacity Building/Networking)
- IP\_2009\_32080

# Promoting South-South Collaboration

- **TBVACSIN** (Tuberculosis Vaccine Trial Sites Network) is a network of partners from Africa and Asia currently involved in or intending to be involved in TB vaccine trials.
  - Share experiences between sites related to TB vaccine trial site development
  - Strengthen TB vaccine trial capacity in African and other countries
  - Network includes sites in South Africa, Kenya, Uganda, Mozambique, Tanzania, India, Cambodia and others.
- Coordinated and led by trial sites in Africa. Northern organizations such as Aeras, KNKV Tuberculosis Foundation and KI are members.

## In conclusion ...



- We all know what is needed
- None of us can do it alone
- We have complimentary capacities and strengths
- Partnerships are already bearing fruit.
- We need to ensure we are all heading the same way!

*Aeras gratefully acknowledges the support of  
the following major donors*

**BILL & MELINDA  
GATES foundation**



**Buitenlandse  
Zaken**

*Netherlands Ministry of Foreign Affairs*



*Ministry of Foreign Affairs of Denmark*

